Suspensions of cyclosporin A form 2

Patent metadata

Field	Value
Publication number	US-10206971-B2
Application number	US-201614995868-A
Country	US
Kind code	B2
Filing date	Jan 14, 2016
Priority date	Nov 15, 2011
Publication date	Feb 19, 2019
Grant date	Feb 19, 2019

Abstract

Disclosed herein are methods of formulating cyclosporin A Form 2.

First claim

What is claimed is:

1. A method of treating a condition selected from dry eye, blepharitis, meibomian gland disease, impaired corneal sensitivity, allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and pterygia, the method comprising the step of administering to a patient having such a condition a formulation comprising particles of cyclosporin A form 2 and a vehicle, wherein the average size (d90) of the particles is less than about 10 μm.

2. The method of claim 1 , wherein the average size of the particles is less than about 1 μm.

3. The method of claim 1 , wherein the condition is dry eye.

Assignees

• Allergan Inc

Inventors

• Gore Anuradha V
• Mohanty Prem Swaroop
• Farnes E Quinn

Classifications

• A61P27/14

  Decongestants or antiallergics · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61K38/13 Primary

  Cyclosporins · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title